a) Blockade of the immunosuppressive functions of both Tregs and MDSCsb) Depletion of TNFR2-expressing Tregs, MDSC, and tumor cells via ADCC and ADCPc) Tumor growth inhibition both as a single agent and in combination with anti-PD-1. This evidence concerns the gene TNFRSF1B and neoplasm.